{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"tesamorelin-carpal-tunnel","title":"Tesamorelin for Carpal Tunnel Syndrome: Evidence Review","body":"## What's breaking down if you have Carpal tunnel syndrome\n\nCarpal tunnel syndrome involves compression of the median nerve inside the narrow carpal tunnel at the wrist. The tunnel is formed by bones and a ligament roof. Swelling or thickening inside this fixed space raises pressure on the nerve. Common contributors include fluid buildup, inflammation of surrounding tissues, repetitive strain, or changes in connective tissue. If fluid retention or soft-tissue expansion is part of your picture, pressure on the nerve can increase symptoms such as numbness, tingling, and weakness.\n\nDegeneration here means ongoing compression outruns any natural repair of the nerve or tunnel tissues. Repair pathways would ideally reduce swelling or improve tissue resilience without adding volume or fluid.\n\n## Why Tesamorelin might help you\n\n1. You are reading about Carpal tunnel syndrome — what breaks down matters before any compound name.\n2. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n\nTesamorelin stimulates growth hormone release via the GH axis and can reduce visceral fat in some contexts. Growth hormone and IGF-1 influence tissue turnover and fluid balance. In theory, if visceral fat or certain metabolic factors contribute to systemic inflammation that affects wrist tissues, changes in that layer could indirectly relate to tunnel pressure. However, increased GH activity is also linked to sodium and water retention that can expand soft tissues.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- Tesamorelin → GH axis / visceral fat\n\nThis single focus means the discussion stays on the GH axis effects and any overlap with carpal tunnel mechanics. No additional peptides are in scope here.\n\n## What the evidence actually shows\n\nNo human trials test tesamorelin as a treatment for carpal tunnel syndrome (human tier: absent). Pharmacovigilance data and prescribing information instead document carpal tunnel syndrome as a reported adverse effect.\n\nA 2025 pharmacovigilance study analyzed over 12 million adverse event reports and found tesamorelin associated with significantly elevated reporting of carpal tunnel syndrome (ROR=20.7) (human tier: observational signal). The FDA label for tesamorelin notes fluid retention effects that can include carpal tunnel syndrome, which are often transient or resolve after stopping the drug (human tier: prescribing information).\n\nGrowth hormone therapies in general have long been linked to carpal tunnel symptoms through fluid retention and soft tissue swelling. One 1993 study observed carpal tunnel syndrome during growth hormone treatment in elderly men (human tier: small trial). Excess GH in conditions like acromegaly also produces similar nerve compression.\n\nNo preclinical (rat or other animal) studies specifically examine tesamorelin for carpal tunnel repair or prevention.\n\n## What scientists say\n\nResearchers note that GH secretagogues like tesamorelin raise circulating GH, which promotes renal sodium retention and can lead to edema in confined spaces such as the carpal tunnel (mechanistic tier). The same pathway that reduces visceral fat can produce musculoskeletal side effects including joint pain and nerve compression in susceptible individuals. Scientists emphasize monitoring for these effects rather than therapeutic use in nerve entrapment conditions.\n\n## What people say on Reddit\n\nAnecdotal reports on forums describe onset of carpal tunnel-like symptoms after starting tesamorelin, with some users linking it to dose or fluid retention. One thread discusses dose reduction to manage symptoms while continuing the peptide (anecdotal tier). Users generally frame it as a side effect to watch rather than a benefit.\n\n## What people say on X\n\nPosts on X mention hand numbness or tingling while using tesamorelin or similar GH secretagogues, often attributed to fluid shifts rather than the original condition (anecdotal tier). Discussions focus on management strategies or discontinuation when symptoms appear.\n\n## What we do not know\n\nNo controlled data exist on whether tesamorelin could improve carpal tunnel through fat loss or tissue repair in any subgroup. Long-term effects on nerve health in people with pre-existing compression remain unstudied. Individual responses to GH-related fluid changes vary widely and cannot be predicted from current evidence.\n\n## Safety and limits\n\nTesamorelin carries labeled warnings for fluid retention and related musculoskeletal effects, including carpal tunnel syndrome. People with existing carpal tunnel are advised caution in prescribing information because the drug may worsen symptoms (human tier: label data). Any discussion of repair pathways must be weighed against documented risk of increased pressure in the tunnel. Evidence does not support use for symptom relief or tissue repair in this condition.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tesamorelin-carpal-tunnel/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Tesamorelin is associated with carpal tunnel syndrome as a reported side effect in pharmacovigilance data.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct signal from large adverse event database relevant to condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.788Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"FDA label for tesamorelin lists fluid retention effects that can include carpal tunnel syndrome.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Official prescribing information confirms adverse effect profile.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.788Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Growth hormone treatment has been linked to carpal tunnel syndrome in clinical observations.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Historical clinical data on GH class effects.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.788Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No human trials evaluate tesamorelin as treatment for carpal tunnel syndrome.","section":"What the evidence actually shows","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Absence of positive evidence for repair use.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.788Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40510111/","title":"Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study","quote":"tesamorelin (ROR=20.7, 95% CI=13.7-31.3)","summary":"Pharmacovigilance analysis showing elevated reporting odds for CTS with tesamorelin.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:25:58.601Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"edd31d00392a11f5512658d208b4635bef7d7a5ee53228c26ecce3796ff8ed9b"},{"id":"s2","type":"medical","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf","title":"EGRIFTA (tesamorelin) Prescribing Information","quote":"It manifests as increased tissue turgor and musculoskeletal discomfort resulting in a variety of adverse reactions (e.g. edema, arthralgia, carpal tunnel syndrome)","summary":"FDA label warning on fluid retention and carpal tunnel effects.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:25:58.601Z","link_status":"ok","quote_status":"unverified","prev":"edd31d00392a11f5512658d208b4635bef7d7a5ee53228c26ecce3796ff8ed9b","hash":"d663614bfc1f5a0e68f6845d0ad1824a6ffa33bcfcb8565677c31292a468198d"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/8287568/","title":"Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men","quote":"Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations.","summary":"Early observation of CTS during GH therapy.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:25:58.601Z","link_status":"ok","quote_status":"unverified","prev":"d663614bfc1f5a0e68f6845d0ad1824a6ffa33bcfcb8565677c31292a468198d","hash":"adaf4d74dc9f98261feb82bc1c5264c83f18cdca21364983e2a1b76e20529872"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:25:59.221Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tesamorelin for Carpal Tunnel Syndrome: Evidence Review","register":"source_ledger","body":"## What's breaking down if you have Carpal tunnel syndrome\n\nCarpal tunnel syndrome involves compression of the median nerve inside the narrow carpal tunnel at the wrist. The tunnel is formed by bones and a ligament roof. Swelling or thickening inside this fixed space raises pressure on the nerve. Common contributors include fluid buildup, inflammation of surrounding tissues, repetitive strain, or changes in connective tissue. If fluid retention or soft-tissue expansion is part of your picture, pressure on the nerve can increase symptoms such as numbness, tingling, and weakness.\n\nDegeneration here means ongoing compression outruns any natural repair of the nerve or tunnel tissues. Repair pathways would ideally reduce swelling or improve tissue resilience without adding volume or fluid.\n\n## Why Tesamorelin might help you\n\n1. You are reading about Carpal tunnel syndrome — what breaks down matters before any compound name.\n2. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n\nTesamorelin stimulates growth hormone release via the GH axis and can reduce visceral fat in some contexts. Growth hormone and IGF-1 influence tissue turnover and fluid balance. In theory, if visceral fat or certain metabolic factors contribute to systemic inflammation that affects wrist tissues, changes in that layer could indirectly relate to tunnel pressure. However, increased GH activity is also linked to sodium and water retention that can expand soft tissues.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- Tesamorelin → GH axis / visceral fat\n\nThis single focus means the discussion stays on the GH axis effects and any overlap with carpal tunnel mechanics. No additional peptides are in scope here.\n\n## What the evidence actually shows\n\nNo human trials test tesamorelin as a treatment for carpal tunnel syndrome (human tier: absent). Pharmacovigilance data and prescribing information instead document carpal tunnel syndrome as a reported adverse effect.\n\nA 2025 pharmacovigilance study analyzed over 12 million adverse event reports and found tesamorelin associated with significantly elevated reporting of carpal tunnel syndrome (ROR=20.7) (human tier: observational signal). The FDA label for tesamorelin notes fluid retention effects that can include carpal tunnel syndrome, which are often transient or resolve after stopping the drug (human tier: prescribing information).\n\nGrowth hormone therapies in general have long been linked to carpal tunnel symptoms through fluid retention and soft tissue swelling. One 1993 study observed carpal tunnel syndrome during growth hormone treatment in elderly men (human tier: small trial). Excess GH in conditions like acromegaly also produces similar nerve compression.\n\nNo preclinical (rat or other animal) studies specifically examine tesamorelin for carpal tunnel repair or prevention.\n\n## What scientists say\n\nResearchers note that GH secretagogues like tesamorelin raise circulating GH, which promotes renal sodium retention and can lead to edema in confined spaces such as the carpal tunnel (mechanistic tier). The same pathway that reduces visceral fat can produce musculoskeletal side effects including joint pain and nerve compression in susceptible individuals. Scientists emphasize monitoring for these effects rather than therapeutic use in nerve entrapment conditions.\n\n## What people say on Reddit\n\nAnecdotal reports on forums describe onset of carpal tunnel-like symptoms after starting tesamorelin, with some users linking it to dose or fluid retention. One thread discusses dose reduction to manage symptoms while continuing the peptide (anecdotal tier). Users generally frame it as a side effect to watch rather than a benefit.\n\n## What people say on X\n\nPosts on X mention hand numbness or tingling while using tesamorelin or similar GH secretagogues, often attributed to fluid shifts rather than the original condition (anecdotal tier). Discussions focus on management strategies or discontinuation when symptoms appear.\n\n## What we do not know\n\nNo controlled data exist on whether tesamorelin could improve carpal tunnel through fat loss or tissue repair in any subgroup. Long-term effects on nerve health in people with pre-existing compression remain unstudied. Individual responses to GH-related fluid changes vary widely and cannot be predicted from current evidence.\n\n## Safety and limits\n\nTesamorelin carries labeled warnings for fluid retention and related musculoskeletal effects, including carpal tunnel syndrome. People with existing carpal tunnel are advised caution in prescribing information because the drug may worsen symptoms (human tier: label data). Any discussion of repair pathways must be weighed against documented risk of increased pressure in the tunnel. Evidence does not support use for symptom relief or tissue repair in this condition.","claims":[{"id":"c1","text":"Tesamorelin is associated with carpal tunnel syndrome as a reported side effect in pharmacovigilance data.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct signal from large adverse event database relevant to condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.788Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"FDA label for tesamorelin lists fluid retention effects that can include carpal tunnel syndrome.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Official prescribing information confirms adverse effect profile.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.788Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Growth hormone treatment has been linked to carpal tunnel syndrome in clinical observations.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Historical clinical data on GH class effects.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.788Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No human trials evaluate tesamorelin as treatment for carpal tunnel syndrome.","section":"What the evidence actually shows","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Absence of positive evidence for repair use.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.788Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40510111/","title":"Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study","quote":"tesamorelin (ROR=20.7, 95% CI=13.7-31.3)","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"medical","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf","title":"EGRIFTA (tesamorelin) Prescribing Information","quote":"It manifests as increased tissue turgor and musculoskeletal discomfort resulting in a variety of adverse reactions (e.g. edema, arthralgia, carpal tunnel syndrome)","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/8287568/","title":"Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men","quote":"Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":11274,"tokens_out":2706,"cost":0.0208575,"prev_hash":"genesis","hash":"e20d80bcac43c8e2b46ee11dd3f34d3431b366bc4af30d2ac8e06df5984d28c5"}],"provenance":[{"ts":"2026-06-29T23:25:59.221Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Carpal Tunnel\nSlug: tesamorelin-carpal-tunnel\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"Carpal tunnel syndrome\",\"condition_key\":\"carpal-tunnel\",\"primary_peptide\":\"tesamorelin\",\"peptides_in_scope\":[{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have Carpal tunnel syndrome\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_title\":\"Why Tesamorelin might help you\",\"layer\":\"GH axis / visceral fat\",\"steps\":[\"You are reading about **Carpal tunnel syndrome** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **Carpal tunnel syndrome** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\",\"section_headings\":[\"What's breaking down if you have ","response":"{\n  \"slug\": \"tesamorelin-carpal-tunnel\",\n  \"title\": \"Tesamorelin for Carpal Tunnel Syndrome: Evidence Review\",\n  \"body\": \"## What's breaking down if you have Carpal tunnel syndrome\\n\\nCarpal tunnel syndrome involves compression of the median nerve inside the narrow carpal tunnel at the wrist. The tunnel is formed by bones and a ligament roof. Swelling or thickening inside this fixed space raises pressure on the nerve. Common contributors include fluid buildup, inflammation of surrounding tissues, repetitive strain, or changes in connective tissue. If fluid retention or soft-tissue expansion is part of your picture, pressure on the nerve can increase symptoms such as numbness, tingling, and weakness.\\n\\nDegeneration here means ongoing compression outruns any natural repair of the nerve or tunnel tissues. Repair pathways would ideally reduce swelling or improve tissue resilience without adding volume or fluid.\\n\\n## Why Tesamorelin might help you\\n\\n1. You are reading about Carpal tunnel syndrome — what breaks down matters before any compound name.\\n2. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nTesamorelin stimulates growth hormone release via the GH axis and can reduce visceral fat in some contexts. Growth hormone and IGF-1 influence tissue turnover and fluid balance. In theory, if visceral fat or certain metabolic factors contribute to systemic inflammation that affects wrist tissues, changes in that layer could indirectly relate to tunnel pressure. However, increased GH activity is also linked to sodium and water retention that can expand soft tissues.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- Tesamorelin → GH axis / visceral fat\\n\\nThis single focus means the discussion stays on the GH axis effects and any overlap with carpa","tokens_in":11274,"tokens_out":2706,"cost":0,"prev":"genesis","hash":"a55861d654c127f8dc95679318438817052ae89d37ead8fcf38a7da2bcb50dd1"},{"ts":"2026-07-17T02:42:20.863Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-carpal-tunnel","response":"25 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a55861d654c127f8dc95679318438817052ae89d37ead8fcf38a7da2bcb50dd1","hash":"8246c9404044f8266b2cbb03674f79905cca679930fe7af4eb0b20d158d43a3d"}],"energy":{"passes":2,"tokens_in":11274,"tokens_out":2706,"tokens_total":13980,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"8246c9404044f8266b2cbb03674f79905cca679930fe7af4eb0b20d158d43a3d"},"posted_at":"2026-06-29T21:33:31.215Z","created_at":"2026-06-29T21:33:31.215Z","updated_at":"2026-07-17T02:42:20.863Z","machine":{"shape":"article.machine/v1","slug":"tesamorelin-carpal-tunnel","kind":"article","read":{"human":"https://miscsubjects.com/a/tesamorelin-carpal-tunnel","json":"https://miscsubjects.com/api/articles/tesamorelin-carpal-tunnel","bundle":"https://miscsubjects.com/api/articles/tesamorelin-carpal-tunnel/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":3,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tesamorelin-carpal-tunnel/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tesamorelin-carpal-tunnel","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-carpal-tunnel\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-carpal-tunnel\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tesamorelin-carpal-tunnel/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tesamorelin-carpal-tunnel\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tesamorelin-carpal-tunnel | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tesamorelin-carpal-tunnel","json":"/api/articles/tesamorelin-carpal-tunnel","markdown":"/api/articles/tesamorelin-carpal-tunnel/bundle?format=markdown","skill":"/api/articles/tesamorelin-carpal-tunnel/skill","topology":"/api/articles/tesamorelin-carpal-tunnel/topology","versions":"/api/articles/tesamorelin-carpal-tunnel/revisions","invocations":"/api/articles/tesamorelin-carpal-tunnel/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tesamorelin-carpal-tunnel","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"ff8f5df40cfb8159eb03d89f72fe5e253d30159b8d934463dd7f8913e6079a75","object":{"object_type":"article-object","identity":{"id":"article:tesamorelin-carpal-tunnel","slug":"tesamorelin-carpal-tunnel","title":"Tesamorelin for Carpal Tunnel Syndrome: Evidence Review"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/tesamorelin-carpal-tunnel","role":"explain","audience":"human"},"skill":{"route":"/api/articles/tesamorelin-carpal-tunnel/skill","role":"direct behavior","audience":"model","content":"---\nname: tesamorelin-carpal-tunnel\ndescription: Apply the Tesamorelin for Carpal Tunnel Syndrome: Evidence Review article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# Tesamorelin for Carpal Tunnel Syndrome: Evidence Review\n\nThis Skill is the behavioral expression of [the canonical article](/a/tesamorelin-carpal-tunnel). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/tesamorelin-carpal-tunnel.\n- Read claims and relationships at /api/articles/tesamorelin-carpal-tunnel/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down if you have Carpal tunnel syndrome Carpal tunnel syndrome involves compression of the median nerve inside the narrow carpal tunnel at the wrist. The tunnel is formed by bones and a ligament roof. Swelling or thickening \n\n## Representations\n\n- Human: /a/tesamorelin-carpal-tunnel\n- JSON: /api/articles/tesamorelin-carpal-tunnel\n- Relationships: /api/articles/tesamorelin-carpal-tunnel/topology\n- History: /api/articles/tesamorelin-carpal-tunnel/revisions\n"},"json":{"route":"/api/articles/tesamorelin-carpal-tunnel","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/tesamorelin-carpal-tunnel/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","tesamorelin","carpal","tunnel"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/tesamorelin-carpal-tunnel/invocations?status=success","failure_events":"/api/articles/tesamorelin-carpal-tunnel/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"tesamorelin-carpal-tunnel","title":"Tesamorelin for Carpal Tunnel Syndrome: Evidence Review","body":"## What's breaking down if you have Carpal tunnel syndrome\n\nCarpal tunnel syndrome involves compression of the median nerve inside the narrow carpal tunnel at the wrist. The tunnel is formed by bones and a ligament roof. Swelling or thickening inside this fixed space raises pressure on the nerve. Common contributors include fluid buildup, inflammation of surrounding tissues, repetitive strain, or changes in connective tissue. If fluid retention or soft-tissue expansion is part of your picture, pressure on the nerve can increase symptoms such as numbness, tingling, and weakness.\n\nDegeneration here means ongoing compression outruns any natural repair of the nerve or tunnel tissues. Repair pathways would ideally reduce swelling or improve tissue resilience without adding volume or fluid.\n\n## Why Tesamorelin might help you\n\n1. You are reading about Carpal tunnel syndrome — what breaks down matters before any compound name.\n2. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n\nTesamorelin stimulates growth hormone release via the GH axis and can reduce visceral fat in some contexts. Growth hormone and IGF-1 influence tissue turnover and fluid balance. In theory, if visceral fat or certain metabolic factors contribute to systemic inflammation that affects wrist tissues, changes in that layer could indirectly relate to tunnel pressure. However, increased GH activity is also linked to sodium and water retention that can expand soft tissues.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- Tesamorelin → GH axis / visceral fat\n\nThis single focus means the discussion stays on the GH axis effects and any overlap with carpal tunnel mechanics. No additional peptides are in scope here.\n\n## What the evidence actually shows\n\nNo human trials test tesamorelin as a treatment for carpal tunnel syndrome (human tier: absent). Pharmacovigilance data and prescribing information instead document carpal tunnel syndrome as a reported adverse effect.\n\nA 2025 pharmacovigilance study analyzed over 12 million adverse event reports and found tesamorelin associated with significantly elevated reporting of carpal tunnel syndrome (ROR=20.7) (human tier: observational signal). The FDA label for tesamorelin notes fluid retention effects that can include carpal tunnel syndrome, which are often transient or resolve after stopping the drug (human tier: prescribing information).\n\nGrowth hormone therapies in general have long been linked to carpal tunnel symptoms through fluid retention and soft tissue swelling. One 1993 study observed carpal tunnel syndrome during growth hormone treatment in elderly men (human tier: small trial). Excess GH in conditions like acromegaly also produces similar nerve compression.\n\nNo preclinical (rat or other animal) studies specifically examine tesamorelin for carpal tunnel repair or prevention.\n\n## What scientists say\n\nResearchers note that GH secretagogues like tesamorelin raise circulating GH, which promotes renal sodium retention and can lead to edema in confined spaces such as the carpal tunnel (mechanistic tier). The same pathway that reduces visceral fat can produce musculoskeletal side effects including joint pain and nerve compression in susceptible individuals. Scientists emphasize monitoring for these effects rather than therapeutic use in nerve entrapment conditions.\n\n## What people say on Reddit\n\nAnecdotal reports on forums describe onset of carpal tunnel-like symptoms after starting tesamorelin, with some users linking it to dose or fluid retention. One thread discusses dose reduction to manage symptoms while continuing the peptide (anecdotal tier). Users generally frame it as a side effect to watch rather than a benefit.\n\n## What people say on X\n\nPosts on X mention hand numbness or tingling while using tesamorelin or similar GH secretagogues, often attributed to fluid shifts rather than the original condition (anecdotal tier). Discussions focus on management strategies or discontinuation when symptoms appear.\n\n## What we do not know\n\nNo controlled data exist on whether tesamorelin could improve carpal tunnel through fat loss or tissue repair in any subgroup. Long-term effects on nerve health in people with pre-existing compression remain unstudied. Individual responses to GH-related fluid changes vary widely and cannot be predicted from current evidence.\n\n## Safety and limits\n\nTesamorelin carries labeled warnings for fluid retention and related musculoskeletal effects, including carpal tunnel syndrome. People with existing carpal tunnel are advised caution in prescribing information because the drug may worsen symptoms (human tier: label data). Any discussion of repair pathways must be weighed against documented risk of increased pressure in the tunnel. Evidence does not support use for symptom relief or tissue repair in this condition.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tesamorelin-carpal-tunnel/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Tesamorelin is associated with carpal tunnel syndrome as a reported side effect in pharmacovigilance data.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct signal from large adverse event database relevant to condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.788Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"FDA label for tesamorelin lists fluid retention effects that can include carpal tunnel syndrome.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Official prescribing information confirms adverse effect profile.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.788Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Growth hormone treatment has been linked to carpal tunnel syndrome in clinical observations.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Historical clinical data on GH class effects.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.788Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No human trials evaluate tesamorelin as treatment for carpal tunnel syndrome.","section":"What the evidence actually shows","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Absence of positive evidence for repair use.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.788Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40510111/","title":"Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study","quote":"tesamorelin (ROR=20.7, 95% CI=13.7-31.3)","summary":"Pharmacovigilance analysis showing elevated reporting odds for CTS with tesamorelin.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:25:58.601Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"edd31d00392a11f5512658d208b4635bef7d7a5ee53228c26ecce3796ff8ed9b"},{"id":"s2","type":"medical","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf","title":"EGRIFTA (tesamorelin) Prescribing Information","quote":"It manifests as increased tissue turgor and musculoskeletal discomfort resulting in a variety of adverse reactions (e.g. edema, arthralgia, carpal tunnel syndrome)","summary":"FDA label warning on fluid retention and carpal tunnel effects.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:25:58.601Z","link_status":"ok","quote_status":"unverified","prev":"edd31d00392a11f5512658d208b4635bef7d7a5ee53228c26ecce3796ff8ed9b","hash":"d663614bfc1f5a0e68f6845d0ad1824a6ffa33bcfcb8565677c31292a468198d"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/8287568/","title":"Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men","quote":"Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations.","summary":"Early observation of CTS during GH therapy.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:25:58.601Z","link_status":"ok","quote_status":"unverified","prev":"d663614bfc1f5a0e68f6845d0ad1824a6ffa33bcfcb8565677c31292a468198d","hash":"adaf4d74dc9f98261feb82bc1c5264c83f18cdca21364983e2a1b76e20529872"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:25:59.221Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tesamorelin for Carpal Tunnel Syndrome: Evidence Review","register":"source_ledger","body":"## What's breaking down if you have Carpal tunnel syndrome\n\nCarpal tunnel syndrome involves compression of the median nerve inside the narrow carpal tunnel at the wrist. The tunnel is formed by bones and a ligament roof. Swelling or thickening inside this fixed space raises pressure on the nerve. Common contributors include fluid buildup, inflammation of surrounding tissues, repetitive strain, or changes in connective tissue. If fluid retention or soft-tissue expansion is part of your picture, pressure on the nerve can increase symptoms such as numbness, tingling, and weakness.\n\nDegeneration here means ongoing compression outruns any natural repair of the nerve or tunnel tissues. Repair pathways would ideally reduce swelling or improve tissue resilience without adding volume or fluid.\n\n## Why Tesamorelin might help you\n\n1. You are reading about Carpal tunnel syndrome — what breaks down matters before any compound name.\n2. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n\nTesamorelin stimulates growth hormone release via the GH axis and can reduce visceral fat in some contexts. Growth hormone and IGF-1 influence tissue turnover and fluid balance. In theory, if visceral fat or certain metabolic factors contribute to systemic inflammation that affects wrist tissues, changes in that layer could indirectly relate to tunnel pressure. However, increased GH activity is also linked to sodium and water retention that can expand soft tissues.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- Tesamorelin → GH axis / visceral fat\n\nThis single focus means the discussion stays on the GH axis effects and any overlap with carpal tunnel mechanics. No additional peptides are in scope here.\n\n## What the evidence actually shows\n\nNo human trials test tesamorelin as a treatment for carpal tunnel syndrome (human tier: absent). Pharmacovigilance data and prescribing information instead document carpal tunnel syndrome as a reported adverse effect.\n\nA 2025 pharmacovigilance study analyzed over 12 million adverse event reports and found tesamorelin associated with significantly elevated reporting of carpal tunnel syndrome (ROR=20.7) (human tier: observational signal). The FDA label for tesamorelin notes fluid retention effects that can include carpal tunnel syndrome, which are often transient or resolve after stopping the drug (human tier: prescribing information).\n\nGrowth hormone therapies in general have long been linked to carpal tunnel symptoms through fluid retention and soft tissue swelling. One 1993 study observed carpal tunnel syndrome during growth hormone treatment in elderly men (human tier: small trial). Excess GH in conditions like acromegaly also produces similar nerve compression.\n\nNo preclinical (rat or other animal) studies specifically examine tesamorelin for carpal tunnel repair or prevention.\n\n## What scientists say\n\nResearchers note that GH secretagogues like tesamorelin raise circulating GH, which promotes renal sodium retention and can lead to edema in confined spaces such as the carpal tunnel (mechanistic tier). The same pathway that reduces visceral fat can produce musculoskeletal side effects including joint pain and nerve compression in susceptible individuals. Scientists emphasize monitoring for these effects rather than therapeutic use in nerve entrapment conditions.\n\n## What people say on Reddit\n\nAnecdotal reports on forums describe onset of carpal tunnel-like symptoms after starting tesamorelin, with some users linking it to dose or fluid retention. One thread discusses dose reduction to manage symptoms while continuing the peptide (anecdotal tier). Users generally frame it as a side effect to watch rather than a benefit.\n\n## What people say on X\n\nPosts on X mention hand numbness or tingling while using tesamorelin or similar GH secretagogues, often attributed to fluid shifts rather than the original condition (anecdotal tier). Discussions focus on management strategies or discontinuation when symptoms appear.\n\n## What we do not know\n\nNo controlled data exist on whether tesamorelin could improve carpal tunnel through fat loss or tissue repair in any subgroup. Long-term effects on nerve health in people with pre-existing compression remain unstudied. Individual responses to GH-related fluid changes vary widely and cannot be predicted from current evidence.\n\n## Safety and limits\n\nTesamorelin carries labeled warnings for fluid retention and related musculoskeletal effects, including carpal tunnel syndrome. People with existing carpal tunnel are advised caution in prescribing information because the drug may worsen symptoms (human tier: label data). Any discussion of repair pathways must be weighed against documented risk of increased pressure in the tunnel. Evidence does not support use for symptom relief or tissue repair in this condition.","claims":[{"id":"c1","text":"Tesamorelin is associated with carpal tunnel syndrome as a reported side effect in pharmacovigilance data.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct signal from large adverse event database relevant to condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.788Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"FDA label for tesamorelin lists fluid retention effects that can include carpal tunnel syndrome.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Official prescribing information confirms adverse effect profile.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.788Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Growth hormone treatment has been linked to carpal tunnel syndrome in clinical observations.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Historical clinical data on GH class effects.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.788Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No human trials evaluate tesamorelin as treatment for carpal tunnel syndrome.","section":"What the evidence actually shows","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Absence of positive evidence for repair use.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.788Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40510111/","title":"Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study","quote":"tesamorelin (ROR=20.7, 95% CI=13.7-31.3)","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"medical","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf","title":"EGRIFTA (tesamorelin) Prescribing Information","quote":"It manifests as increased tissue turgor and musculoskeletal discomfort resulting in a variety of adverse reactions (e.g. edema, arthralgia, carpal tunnel syndrome)","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/8287568/","title":"Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men","quote":"Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":11274,"tokens_out":2706,"cost":0.0208575,"prev_hash":"genesis","hash":"e20d80bcac43c8e2b46ee11dd3f34d3431b366bc4af30d2ac8e06df5984d28c5"}],"provenance":[{"ts":"2026-06-29T23:25:59.221Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Carpal Tunnel\nSlug: tesamorelin-carpal-tunnel\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"Carpal tunnel syndrome\",\"condition_key\":\"carpal-tunnel\",\"primary_peptide\":\"tesamorelin\",\"peptides_in_scope\":[{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have Carpal tunnel syndrome\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_title\":\"Why Tesamorelin might help you\",\"layer\":\"GH axis / visceral fat\",\"steps\":[\"You are reading about **Carpal tunnel syndrome** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **Carpal tunnel syndrome** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\",\"section_headings\":[\"What's breaking down if you have ","response":"{\n  \"slug\": \"tesamorelin-carpal-tunnel\",\n  \"title\": \"Tesamorelin for Carpal Tunnel Syndrome: Evidence Review\",\n  \"body\": \"## What's breaking down if you have Carpal tunnel syndrome\\n\\nCarpal tunnel syndrome involves compression of the median nerve inside the narrow carpal tunnel at the wrist. The tunnel is formed by bones and a ligament roof. Swelling or thickening inside this fixed space raises pressure on the nerve. Common contributors include fluid buildup, inflammation of surrounding tissues, repetitive strain, or changes in connective tissue. If fluid retention or soft-tissue expansion is part of your picture, pressure on the nerve can increase symptoms such as numbness, tingling, and weakness.\\n\\nDegeneration here means ongoing compression outruns any natural repair of the nerve or tunnel tissues. Repair pathways would ideally reduce swelling or improve tissue resilience without adding volume or fluid.\\n\\n## Why Tesamorelin might help you\\n\\n1. You are reading about Carpal tunnel syndrome — what breaks down matters before any compound name.\\n2. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nTesamorelin stimulates growth hormone release via the GH axis and can reduce visceral fat in some contexts. Growth hormone and IGF-1 influence tissue turnover and fluid balance. In theory, if visceral fat or certain metabolic factors contribute to systemic inflammation that affects wrist tissues, changes in that layer could indirectly relate to tunnel pressure. However, increased GH activity is also linked to sodium and water retention that can expand soft tissues.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- Tesamorelin → GH axis / visceral fat\\n\\nThis single focus means the discussion stays on the GH axis effects and any overlap with carpa","tokens_in":11274,"tokens_out":2706,"cost":0,"prev":"genesis","hash":"a55861d654c127f8dc95679318438817052ae89d37ead8fcf38a7da2bcb50dd1"},{"ts":"2026-07-17T02:42:20.863Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-carpal-tunnel","response":"25 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a55861d654c127f8dc95679318438817052ae89d37ead8fcf38a7da2bcb50dd1","hash":"8246c9404044f8266b2cbb03674f79905cca679930fe7af4eb0b20d158d43a3d"}],"energy":{"passes":2,"tokens_in":11274,"tokens_out":2706,"tokens_total":13980,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"8246c9404044f8266b2cbb03674f79905cca679930fe7af4eb0b20d158d43a3d"},"posted_at":"2026-06-29T21:33:31.215Z","created_at":"2026-06-29T21:33:31.215Z","updated_at":"2026-07-17T02:42:20.863Z","machine":{"shape":"article.machine/v1","slug":"tesamorelin-carpal-tunnel","kind":"article","read":{"human":"https://miscsubjects.com/a/tesamorelin-carpal-tunnel","json":"https://miscsubjects.com/api/articles/tesamorelin-carpal-tunnel","bundle":"https://miscsubjects.com/api/articles/tesamorelin-carpal-tunnel/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":3,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tesamorelin-carpal-tunnel/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tesamorelin-carpal-tunnel","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-carpal-tunnel\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-carpal-tunnel\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tesamorelin-carpal-tunnel/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tesamorelin-carpal-tunnel\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tesamorelin-carpal-tunnel | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tesamorelin-carpal-tunnel","json":"/api/articles/tesamorelin-carpal-tunnel","markdown":"/api/articles/tesamorelin-carpal-tunnel/bundle?format=markdown","skill":"/api/articles/tesamorelin-carpal-tunnel/skill","topology":"/api/articles/tesamorelin-carpal-tunnel/topology","versions":"/api/articles/tesamorelin-carpal-tunnel/revisions","invocations":"/api/articles/tesamorelin-carpal-tunnel/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tesamorelin-carpal-tunnel","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"ff8f5df40cfb8159eb03d89f72fe5e253d30159b8d934463dd7f8913e6079a75"}}}